RELEVANT PUBLICATIONS FROM KEY AUTHORS
Wibowo, E., Wassersug, R. J., Robinson, J. W., Matthew, A., McLeod, D. L., Walker, L. M. 2018. The influence of an Androgen Deprivation Therapy Educational Program on dyadic quality and intimacy for prostate cancer patients and their partners. J Clin Oncol. 36 (Suppl 7S): abstr 178. Presented at the 2018 Cancer Survivorship Symposium, Orlando, FL.
Wassersug, R. J., Wibowo, E. 2017. Non-pharmacological and non-surgical strategies for sexual recovery by men with erectile dysfunction. (Invited review) Trans Androl Urol. 6(Suppl. 5):S776-794. tau.amegroups.com/article/view/15068/15218
Wibowo, E., Wassersug, R. J., Robinson, J. W., Matthew, A., McLeod, D. L., Wilyman, S., Walker, L. M. 2017. A preliminary evaluation of the TrueNTH androgen deprivation therapy educational program. J Clin Oncol. 35(Suppl 5S):abstr 219. Presented at the 2017 Cancer Survivorship Symposium, San Diego, CA.
Rot I, Wassersug RJ, Walker LM. 2016. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product. Transl Androl Urol. 5:235-247. www.ncbi.nlm.nih.gov/pubmed/27197037
Robinson, J., Wassersug, R. J., Walker, L. M., McLeod, D. L., Matthew, A., Wibowo E. 2016. The androgen-deprivation therapy educational program: A Canadian True NTH initiative. Psychooncology. 25(Sp. S 3):21. Abstr 60. Presented at the International Psychooncology Society Congress, Dublin, Ireland.
Robinson, J. W., Wassersug, R. J., Walker, L. M., Wibowo, E., Matthew, A., McLeod, D. L. 2016. The androgen deprivation therapy educational program: A Canadian TrueNTH initiative. CUAJ. 10(Suppl 1):S79, Abstract: UP-07.10. Presented at the 2016 Canadian Urological Association Annual Meeting, Vancouver, BC.
Wibowo, E., Walker, L. M., Wilyman, S., Matthew, A., McLeod, D. L., Wassersug, R. J., Robinson, J. W. 2016. Androgen deprivation therapy educational program: A Canadian True NTH initiative. J Clin Oncol. 34(Suppl 3S):abstr 243. Presented at Cancer Survivorship Symposium, San Francisco, CA.
Lee TK, Handy AB, Kwan W, Oliffe JL, Brotto LA, Wassersug RJ, Dowsett GW. 2015. Impact of prostate cancer treatment on the sexual quality of life for men-who-have-sex-with-men. J Sex Med 12:2378-86. www.ncbi.nlm.nih.gov/pubmed/26537853
Hamilton LD, Van Dam D, Wassersug RJ. 2015. The perspective of prostate cancer patients and patients' partners on the psychological burden of androgen deprivation and the dyadic adjustment of prostate cancer couples. Psychooncology 25:823-31. www.ncbi.nlm.nih.gov/pubmed/26411285
Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. 2015. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 121:4286-99. www.ncbi.nlm.nih.gov/pubmed/26372364
Van Dam D, Wassersug RJ, Hamilton LD. 2015. Androgen deprivation therapy’s impact on the mood of prostate cancer patients as perceived by patients and the partners of patients. Psycho-Oncology 25:848-56. www.ncbi.nlm.nih.gov/pubmed/26332203
McLeod DL, Walker LM, Wassersug RJ, Matthew A, Robinson JW. 2014. The sexual and other supportive care needs of Canadian prostate cancer patients and their partners: Defining the problem and developing interventions. Canadian Oncology Nursing Journal 24:272-278. http://www.canadianoncologynursingjournal.com/index.php/conj/article/view/59
Tran S, Walker LM, Wassersug RW, Matthew AG, McLeod DL, Robinson JW. 2014. What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy? J Oncol Pharm Pract. 20:199-209. http://www.ncbi.nlm.nih.gov/pubmed/2412285
Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW. 2013. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol 31:1098-1105. http://www.ncbi.nlm.nih.gov/pubmed/22285008
Walker LM, Tran S, Robinson JW. 2013. Luteinizing hormone—releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer. 11:375-384. http://www.ncbi.nlm.nih.gov/pubmed/23891497
Kukula KC, Jackowich RA, Wassersug RW. 2013. Eroticization as a factor influencing ED treatment effectiveness. Inter J Impotence Res. 26:1-6. http://www.ncbi.nlm.nih.gov/pubmed/23823215
Wassersug RJ. 2013. Extending the case for oestradiol in androgen-sensitive prostate cancer. Lancet Oncol. 14:e242-3. http://www.ncbi.nlm.nih.gov/pubmed/23725706
Walker LM, Hampton AJ, Wassersug RJ, Thomas BC, Robinson RJ. 2013. Androgen deprivation therapy and maintenance of intimacy: A randomized controlled pilot study of an educational intervention for patients and their partners. Contemp Clinical Trials 34:227-231. http://www.ncbi.nlm.nih.gov/pubmed/23220254
Wibowo E, Deurveilher S, Wassersug RJ, Semba K. 2012. Estradiol treatment modulates spontaneous sleep and sleep recovery after sleep deprivation in castrated male rats. Behav Brain Res. 226:456-464. http://www.ncbi.nlm.nih.gov/pubmed/22004978
Walker L, Tran S, Wassersug RJ, Thomas B, Robinson J. 2012. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol. 31:1098-105. http://www.ncbi.nlm.nih.gov/pubmed/22285008
Rot I, Ogah I, Wassersug RJ. 2012. The language of prostate cancer treatments and implications for informed decision making by patients and their partners. Eur J Cancer Care. 21:766-775. http://www.ncbi.nlm.nih.gov/pubmed/22574619
Wibowo E, Wassersug R, Warkentin K, Walker L, Robinson J, Brotto L, Johnson T. 2012. Impact of androgen deprivation therapy on sexual function: A response. Asian J Androl. 14:793-794. http://www.ncbi.nlm.nih.gov/pubmed/22796736
Phillips JL, Wassersug RJ, McLeod D. 2012. Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice. Int J Clin Practice. 66:1189-1196. http://www.ncbi.nlm.nih.gov/pubmed/23163498
Ogah I, Wassersug RJ. 2012. How reliable are "reputable sources" for medical information on the internet?—The case of hormonal therapy to treat prostate cancer. Urol Oncol. 31:1546-1552. http://www.ncbi.nlm.nih.gov/pubmed/23141782
Aning JJ, RJ Wassersug RJ, Goldenberg LS. 2012. Patient preferences and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Current Oncol. 19:S37-S44. http://www.ncbi.nlm.nih.gov/pubmed/23355792
Murphy R, Wassersug RJ, Dechman G. 2011. The role of exercise in managing the adverse effects of androgen deprivation therapy in men with prostate cancer. Phys Therapy Rev. 16:269-277. http://www.maneyonline.com/doi/abs/10.1179/1743288X11Y.0000000029
Wibowo E, Schellhammer P, Wassersug RJ. 2011. Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol, 185:17-23. http://www.ncbi.nlm.nih.gov/pubmed/21074215
Elliott S, Latini DM, Walker LM, Wassersug RJ, Robinson JW. 2010. Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life. J Sex Med. 7: 2996–3010. http://www.ncbi.nlm.nih.gov/pubmed/20626600
Wassersug RJ. 2009. Mastering emasculation. J Clin Oncol. 27:634-636. http://jco.ascopubs.org/content/27/4/634.full